Nwam LLC Cuts Position in GSK plc (NYSE:GSK)

Nwam LLC reduced its position in GSK plc (NYSE:GSK) by 41.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,920 shares of the pharmaceutical company’s stock after selling 6,365 shares during the period. Nwam LLC’s holdings in GSK were worth $302,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. FMR LLC lifted its position in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Clifford Capital Partners LLC lifted its holdings in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares in the last quarter. Cerity Partners LLC boosted its position in GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after purchasing an additional 165,556 shares during the period. Finally, Natixis Advisors LLC increased its holdings in GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after purchasing an additional 83,433 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $37.59 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The business has a 50 day moving average price of $34.99 and a two-hundred day moving average price of $37.26. The firm has a market cap of $77.90 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.